US6054561A
(en)
*
|
1984-02-08 |
2000-04-25 |
Chiron Corporation |
Antigen-binding sites of antibody molecules specific for cancer antigens
|
US5032521A
(en)
*
|
1984-12-05 |
1991-07-16 |
The Salk Institute For Biological Studies |
Monoclonal antibody specific for a mammary tumor cell surface antigen
|
AU601379B2
(en)
*
|
1985-11-07 |
1990-09-13 |
Trustees Of Columbia University In The City Of New York, The |
Antigen indicative of human breast cancer and assays based thereon
|
US5401638A
(en)
*
|
1986-06-04 |
1995-03-28 |
Oncogene Science, Inc. |
Detection and quantification of neu related proteins in the biological fluids of humans
|
US6861511B1
(en)
|
1986-06-04 |
2005-03-01 |
Bayer Corporation |
Detection and quantification of neu related proteins in the biological fluids of humans
|
US4894227A
(en)
*
|
1986-08-01 |
1990-01-16 |
Cetus Corporation |
Composition of immunotoxins with interleukin-2
|
US6004761A
(en)
*
|
1986-11-19 |
1999-12-21 |
Sanofi |
Method for detecting cancer using monoclonal antibodies to new mucin epitopes
|
AU613590B2
(en)
*
|
1986-11-19 |
1991-08-08 |
Bristol-Myers Squibb Company |
Hybridomas producing monoclonal antibodies to new mucin epitopes
|
US4863726A
(en)
*
|
1987-05-29 |
1989-09-05 |
Cetus Corporation |
Combination therapy using immunotoxins with interleukin-2
|
US5084266A
(en)
*
|
1988-02-03 |
1992-01-28 |
The University Of Melbourne |
Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody
|
US5681543A
(en)
*
|
1988-02-29 |
1997-10-28 |
Shering Aktiengesellschaft |
Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
|
US5948647A
(en)
*
|
1990-10-29 |
1999-09-07 |
Chiron Corporation |
Nucleic acids encoding antigen-binding sites specific for cancer antigens
|
US5811267A
(en)
*
|
1990-10-29 |
1998-09-22 |
Chiron Corporation |
Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
|
US5849877A
(en)
*
|
1990-10-29 |
1998-12-15 |
Chiron Corporation |
Antigen-binding sites of antibody molecules specific for cancer antigens
|
US5292524A
(en)
*
|
1991-09-06 |
1994-03-08 |
California Institute Of Technology |
Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
|
DE69333807T2
(de)
*
|
1992-02-06 |
2006-02-02 |
Chiron Corp., Emeryville |
Marker für krebs und biosynthetisches bindeprotein dafür
|
US7255851B2
(en)
*
|
1994-07-01 |
2007-08-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-invasive localization of a light-emitting conjugate in a mammal
|
US20030086922A1
(en)
*
|
1994-12-02 |
2003-05-08 |
David B. Ring |
Method of promoting an immune response with a bispecific antibody
|
US6416960B1
(en)
|
1996-08-08 |
2002-07-09 |
Prolume, Ltd. |
Detection and visualization of neoplastic tissues and other tissues
|
GB9906380D0
(en)
*
|
1999-03-19 |
1999-05-12 |
Melvin William T |
Monoclonal antibodies specific for cypibi
|
FR2811323B1
(fr)
*
|
2000-07-07 |
2006-10-06 |
Fuma Tech Gmbh |
Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
|
DE10141937A1
(de)
*
|
2001-08-28 |
2003-03-27 |
Alfred Schmidt |
Markierung der Aromatase
|
ATE443259T1
(de)
|
2001-09-20 |
2009-10-15 |
Univ Texas |
Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
|
US20040126762A1
(en)
*
|
2002-12-17 |
2004-07-01 |
Morris David W. |
Novel compositions and methods in cancer
|
US20040166490A1
(en)
*
|
2002-12-17 |
2004-08-26 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20060040262A1
(en)
*
|
2002-12-27 |
2006-02-23 |
Morris David W |
Novel compositions and methods in cancer
|
US20040180344A1
(en)
*
|
2003-03-14 |
2004-09-16 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20040197778A1
(en)
*
|
2002-12-26 |
2004-10-07 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US20040023267A1
(en)
*
|
2002-03-21 |
2004-02-05 |
Morris David W. |
Novel compositions and methods in cancer
|
CA2501188C
(en)
|
2002-07-15 |
2012-05-15 |
Board Of Regents, The University Of Texas System |
Combinatorial protein library screening by periplasmic expression
|
US7794716B2
(en)
|
2002-07-25 |
2010-09-14 |
Glenveigh Pharmaceuticals, Llc |
Antibody composition and passive immunization against pregnancy-induced hypertension
|
US20070218071A1
(en)
*
|
2003-09-15 |
2007-09-20 |
Morris David W |
Novel therapeutic targets in cancer
|
US20040170982A1
(en)
*
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
US7767387B2
(en)
*
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
WO2004074321A2
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic gpcr targets in cancer
|
US20070281896A1
(en)
*
|
2003-09-30 |
2007-12-06 |
Morris David W |
Novel compositions and methods in cancer
|
CN1925871A
(zh)
*
|
2004-01-27 |
2007-03-07 |
南加州大学 |
聚合物结合的抗体癌症治疗剂
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
CN101043891A
(zh)
|
2004-09-18 |
2007-09-26 |
巴尔的摩马里兰大学 |
靶向NCCa-ATP通道的治疗剂及其使用方法
|
EP1799227B1
(en)
|
2004-09-18 |
2010-11-10 |
University of Maryland, Baltimore |
Therapeutic agents targeting the nc ca-atp channel and methods of use thereof
|
EP1872136B9
(en)
|
2005-04-04 |
2023-02-08 |
Biogen MA Inc. |
Methods and products for evaluating an immune response to a therapeutic protein
|
US20090220495A1
(en)
|
2005-04-07 |
2009-09-03 |
Abdallah Fanidi |
Cancer Related Genes (PRLR)
|
US20090214536A1
(en)
|
2005-04-07 |
2009-08-27 |
Guoying Yu |
CACNA1E in Cancer Diagnosis, Detection and Treatment
|
DE212006000071U1
(de)
|
2005-11-18 |
2008-07-24 |
Board of Regents, The University of Texas System, Austin |
Quantifizierung von Fusionsproteinen und ihrer Aktivität in Folge chromosomaler Translokation
|
CN101505795B
(zh)
|
2006-07-03 |
2013-02-13 |
查尔斯·戴维·阿代尔 |
用于调节细胞粘附分子表达的组合物
|
CA2671264C
(en)
|
2006-11-30 |
2015-11-24 |
Research Development Foundation |
Improved immunoglobulin libraries
|
CA2674949A1
(en)
|
2007-01-12 |
2008-07-24 |
J. Marc Simard |
Targeting ncca-atp channel for organ protection following ischemic episode
|
KR100855299B1
(ko)
*
|
2007-02-16 |
2008-08-29 |
건국대학교 산학협력단 |
인간 il-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 il-32측정법
|
AU2008247819B2
(en)
|
2007-05-01 |
2013-02-14 |
Research Development Foundation |
Immunoglobulin Fc libraries
|
US8252897B2
(en)
*
|
2007-06-21 |
2012-08-28 |
Angelica Therapeutics, Inc. |
Modified toxins
|
US8715743B2
(en)
|
2007-08-03 |
2014-05-06 |
Musc Foundation For Research Development |
Human monoclonal antibodies and methods for producing the same
|
EP2944649A1
(en)
|
2008-01-10 |
2015-11-18 |
Research Development Foundation |
Vaccines and diagnostics for the ehrlichioses
|
US8470314B2
(en)
*
|
2008-02-29 |
2013-06-25 |
Angelica Therapeutics, Inc. |
Modified toxins
|
US20100082438A1
(en)
*
|
2008-10-01 |
2010-04-01 |
Ronnie Jack Garmon |
Methods and systems for customer performance scoring
|
JP5805538B2
(ja)
|
2008-11-07 |
2015-11-04 |
リサーチ ディベロップメント ファウンデーション |
Cripto/GSP78複合体形成およびシグナル伝達を阻害するための組成物および方法
|
CA2745111A1
(en)
|
2008-12-03 |
2010-06-10 |
Research Development Foundation |
Modulation of olfml-3 mediated angiogenesis
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
ES2666372T3
(es)
|
2009-10-11 |
2018-05-04 |
Biogen Ma Inc. |
Ensayos relacionados con anti-VLA-4
|
EP2501800A4
(en)
|
2009-11-17 |
2013-05-22 |
Musc Found For Res Dev |
HUMAN MONOCLONAL ANTIBODIES FOR HUMAN NUCLEOLIN
|
US9309322B2
(en)
|
2010-11-12 |
2016-04-12 |
Scott & White Healthcare (Swh) |
Antibodies to tumor endothelial marker 8
|
CA2826467C
(en)
|
2011-02-07 |
2019-11-12 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides
|
KR102489185B1
(ko)
|
2011-04-01 |
2023-01-17 |
이뮤노젠 아이엔씨 |
Folr1 암 치료의 효능을 증가시키기 위한 방법
|
AU2012294814A1
(en)
|
2011-08-05 |
2014-02-27 |
Research Development Foundation |
Improved methods and compositions for modulation of Olfml3 mediated angiogenesis
|
EP2744517B1
(en)
|
2011-08-15 |
2019-03-13 |
The University of Chicago |
Compositions and methods related to antibodies to staphylococcal protein a
|
RS58910B1
(sr)
|
2012-03-20 |
2019-08-30 |
Biogen Ma Inc |
Antitela koja neutrališu virus jcv
|
CN104703622B
(zh)
|
2012-04-26 |
2017-05-24 |
芝加哥大学 |
与金黄色葡萄球菌疾病期间抵消凝固酶活性的抗体相关的组合物和方法
|
CA2871160C
(en)
|
2012-05-10 |
2023-03-14 |
Massachusetts Institute Of Technology |
Agents for influenza neutralization
|
EP2882453B1
(en)
|
2012-08-07 |
2021-01-06 |
Massachusetts Institute of Technology |
Anti-dengue virus antibodies and uses thereof
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
CA2888345C
(en)
|
2012-10-24 |
2020-04-21 |
Research Development Foundation |
Jam-c antibodies and methods for treatment of cancer
|
US9388397B2
(en)
|
2013-02-15 |
2016-07-12 |
Research Development Foundation |
Deimmunized gelonin molecules and therapies
|
JP6463331B2
(ja)
|
2013-03-15 |
2019-01-30 |
イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー |
抗ヘプシジン抗体およびその使用
|
CA2902905A1
(en)
|
2013-03-15 |
2014-09-25 |
Claude Geoffrey Davis |
Modified toxins
|
US9944992B2
(en)
|
2013-03-15 |
2018-04-17 |
The University Of Chicago |
Methods and compositions related to T-cell activity
|
EP4174082A1
(en)
|
2013-03-15 |
2023-05-03 |
GLAdiator Biosciences, Inc. |
Gla domains as targeting agents
|
WO2014197723A2
(en)
|
2013-06-05 |
2014-12-11 |
Massachusetts Institute Of Technology |
Human adaptation of h7 ha
|
AU2014302082B2
(en)
|
2013-06-28 |
2019-08-08 |
Baylor Research Institute |
Dendritic cell ASGPR targeting immunotherapeutics for multiple sclerosis
|
US9914775B2
(en)
|
2013-08-21 |
2018-03-13 |
The Board Of Regents Of The University Of Texas System |
Methods for treating inflammatory disorders or cancer metastasis by administering antibodies to connexin 43 (Cx43) hemichannels
|
SG10201907501QA
(en)
|
2013-08-30 |
2019-10-30 |
Immunogen Inc |
Antibodies and assays for detection of folate receptor 1
|
US20170002064A1
(en)
|
2013-11-08 |
2017-01-05 |
The Board Of Regents Of The University Of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
US10286058B2
(en)
|
2014-01-13 |
2019-05-14 |
Baylor Research Institute |
Vaccines against HPV and HPV-related diseases
|
EP3099719B1
(en)
|
2014-01-29 |
2020-04-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
|
JP6707455B2
(ja)
|
2014-02-11 |
2020-06-10 |
マサチューセッツ インスティテュート オブ テクノロジー |
新規フルスペクトル抗デング抗体
|
EP3140653B1
(en)
|
2014-05-08 |
2022-05-11 |
Novodiax, Inc. |
Direct immunohistochemistry assay
|
WO2015179435A1
(en)
|
2014-05-19 |
2015-11-26 |
Bayer Healthcare Llc |
Optimized humanized monoclonal antibodies against activated protein c and uses thereof
|
KR102485788B1
(ko)
|
2014-08-27 |
2023-01-09 |
메모리얼 슬로안 케터링 캔서 센터 |
항체, 조성물 및 용도
|
EP3197915A4
(en)
|
2014-09-22 |
2018-12-19 |
Intrinsic Lifesciences LLC |
Humanized anti-hepcidin antibodies and uses thereof
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
US10155820B2
(en)
|
2014-11-12 |
2018-12-18 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
WO2016130539A2
(en)
|
2015-02-09 |
2016-08-18 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
|
EP3256490A1
(en)
|
2015-02-09 |
2017-12-20 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
DK3262411T3
(da)
|
2015-02-25 |
2022-04-19 |
Univ Vanderbilt |
Antibody-mediated neutralization of marburg virus
|
US10526408B2
(en)
|
2015-08-28 |
2020-01-07 |
Research Development Foundation |
Engineered antibody FC variants
|
FI3373968T3
(fi)
|
2015-11-09 |
2024-07-17 |
Childrens Hospital Philadelphia |
Glypikaani 2 syövän merkkiaineena ja terapeuttisena kohteena
|
MX2018006613A
(es)
|
2015-12-02 |
2019-01-30 |
Stcube & Co Inc |
Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
|
JP7227007B2
(ja)
|
2015-12-02 |
2023-02-21 |
ストサイエンシス, インコーポレイテッド |
グリコシル化btla(b-及びt-リンパ球減弱因子)に特異的な抗体
|
EP3383418B1
(en)
|
2015-12-04 |
2021-10-20 |
Board of Regents, The University of Texas System |
Slc45a2 peptides for immunotherapy
|
AU2017224122B2
(en)
|
2016-02-26 |
2024-04-11 |
The Board Of Regents Of The University Of Texas System |
Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
|
CN109195991B
(zh)
|
2016-03-29 |
2023-10-31 |
斯特库比股份有限公司 |
对糖基化pd-l1特异的双重功能抗体及其使用方法
|
CN109195990A
(zh)
|
2016-03-30 |
2019-01-11 |
Musc研究发展基金会 |
通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
|
US11559590B2
(en)
|
2016-07-01 |
2023-01-24 |
The General Hospital Corporation |
Granzyme B directed imaging and therapy
|
WO2018017673A1
(en)
|
2016-07-20 |
2018-01-25 |
Stcube, Inc. |
Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
|
WO2018126183A2
(en)
|
2016-12-29 |
2018-07-05 |
The General Hospital Corporation |
Her3 peptides for imaging and radiotherapy
|
AU2018214946A1
(en)
|
2017-01-31 |
2019-08-08 |
Vanderbilt University |
Generation of human allergen-and helminth-specific IgE monoclonal antibodies for diagnostic and therapeutic use
|
WO2018222689A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
JP2020522512A
(ja)
|
2017-05-31 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
|
US11542331B2
(en)
|
2017-06-06 |
2023-01-03 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
|
US10759865B2
(en)
|
2017-08-22 |
2020-09-01 |
Eyal Levit |
Treatment of diabetes mellitus
|
CN111094352A
(zh)
|
2017-08-25 |
2020-05-01 |
戊瑞治疗有限公司 |
B7-h4抗体及其使用方法
|
US11981723B2
(en)
|
2017-09-05 |
2024-05-14 |
GLAdiator Biosciences, Inc. |
Method of targeting exosomes
|
US11464784B2
(en)
|
2017-09-15 |
2022-10-11 |
The Regents Of The University Of California |
Inhibition of aminocylase 3 (AA3) in the treatment of cancer
|
EP3694545A4
(en)
|
2017-10-11 |
2021-12-01 |
Board Of Regents, The University Of Texas System |
HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM
|
WO2019156758A2
(en)
|
2018-01-05 |
2019-08-15 |
Vanderbilt University |
Antibody-mediated neutralization of chikungunya virus
|
AU2019228600A1
(en)
|
2018-03-02 |
2020-09-24 |
Five Prime Therapeutics, Inc. |
B7-H4 antibodies and methods of use thereof
|
US20210214445A1
(en)
|
2018-03-23 |
2021-07-15 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
|
EP3849608B1
(en)
|
2018-09-13 |
2023-08-30 |
The Board of Regents of The University of Texas System |
Novel lilrb4 antibodies and uses thereof
|
EP3873514A4
(en)
|
2018-11-02 |
2022-11-02 |
Oklahoma Medical Research Foundation |
MONOCLONAL ANTIBODIES AGAINST ELTD1 AND THEIR USES
|
US20220089776A1
(en)
|
2018-11-28 |
2022-03-24 |
Oregon Health & Science University |
Therapeutic factor xii antibody
|
EP3924354A1
(en)
|
2019-02-13 |
2021-12-22 |
Cytosite Biopharma Inc. |
Granzyme b directed imaging and therapy
|
AU2020317009A1
(en)
|
2019-07-19 |
2022-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric antigen receptors containing Glypican 2 binding domains
|
EP4004037A1
(en)
|
2019-07-26 |
2022-06-01 |
Vanderbilt University |
Human monoclonal antibodies to enterovirus d68
|
EP4041767A1
(en)
|
2019-09-26 |
2022-08-17 |
StCube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
JP2022552282A
(ja)
|
2019-10-09 |
2022-12-15 |
エスティーキューブ アンド カンパニー |
グリコシル化lag3に対して特異的な抗体およびその使用方法
|
KR20220140568A
(ko)
|
2020-02-11 |
2022-10-18 |
벤더르빌트 유니버시티 |
중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체
|
WO2021167908A1
(en)
|
2020-02-17 |
2021-08-26 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
PT4045533T
(pt)
|
2020-03-26 |
2024-02-14 |
Univ Vanderbilt |
Anticorpos monoclonais humanos para síndrome respiratória aguda grave coronavírus 2 (sars-cov-2)
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
GB202105804D0
(en)
|
2020-11-20 |
2021-06-09 |
Univ Cape Town |
Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
CN117729942A
(zh)
|
2021-03-08 |
2024-03-19 |
伊缪诺金公司 |
用于增加靶向adam9的免疫缀合物治疗癌症的功效的方法
|
GB202201137D0
(en)
|
2022-01-28 |
2022-03-16 |
Thelper As |
Therapeutic and diagnostic agents and uses thereof
|
US20230365708A1
(en)
|
2022-04-01 |
2023-11-16 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
WO2023239940A1
(en)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
WO2024040020A1
(en)
|
2022-08-15 |
2024-02-22 |
Absci Corporation |
Quantitative affinity activity specific cell enrichment
|